Cancer Family
Intestinal Neoplasm
CI-CAN-00000209Explore in graph →
Non-malignant1,892 active trials21 approved drugs383 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000209Explore in graph →
Clinical trials
9,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01902823 | Effect of Cancer Nurse Navigators on Patient Outcomes | terminated | Phase 2 / Phase 3 | 16 | University of Wisconsin, MadisonOTHER | 1 | Dec 13, 2019 | clinicaltrials |
| NCT02318901 | Pembrolizumab and Monoclonal Antibody Therapy in Advanced Cancer(PembroMab) | terminated | Phase 1 / Phase 2 | 16 | Western Regional Medical CenterOTHER | 1 | Oct 21, 2019 | clinicaltrials |
| NCT02685046 | Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy(ImPACCT) | terminated | Phase 2 | 5 | UMC UtrechtOTHER | 1 | Oct 14, 2019 | clinicaltrials |
| NCT00397878 | AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2019 | clinicaltrials |
| NCT03204201 | Validation of ICG to Identify the Urethra During Rectal Surgery | terminated | Phase 1 / Phase 2 | 5 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03204994 | Fluorescence Targeted Pelvic Lymph Node Mapping | terminated | Phase 1 / Phase 2 | 1 | Oxford University Hospitals NHS TrustOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT03431311 | T Cell Receptor Based Therapy of Metastatic Colorectal Cancer(TCR-CRC-001) | terminated | Phase 1 / Phase 2 | 1 | Oslo University HospitalOTHER | 1 | Jun 13, 2019 | clinicaltrials |
| NCT03645876 | SHR-1210 in Combination With BP102 and XELOX in Patient With Metastatic Colorectal Cancer | terminated | Phase 2 | 12 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | May 10, 2019 | clinicaltrials |
| NCT03070574 | Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome(MesaCAPP) | terminated | Phase 2 | 8 | Christoph GascheOTHER | 6 | Apr 18, 2019 | clinicaltrials |
| NCT01479465 | Efficacy and Safety of Simtuzumab (SIM) With FOLFIRI as Second Line Treatment in Colorectal Adenocarcinoma | terminated | Phase 2 | 266 | Gilead SciencesINDUSTRY | 7 | Apr 17, 2019 | clinicaltrials |
| NCT02568046 | Sym004 in Combination With FOLFIRI in Metastatic Colorectal Cancer Patients | terminated | Phase 1 / Phase 2 | 10 | Symphogen A/SINDUSTRY | 2 | Mar 26, 2019 | clinicaltrials |
| NCT02584400 | Tumor Hypoxia With HX4 PET in Several Diseases(HX4 SD) | terminated | Phase 2 | 1 | Maastricht Radiation OncologyOTHER | 1 | Mar 8, 2019 | clinicaltrials |
| NCT02402036 | A Biomarker Study in Patients Getting Regorafenib for Metastatic Colorectal Cancer | terminated | Phase 2 | 10 | Georgetown UniversityOTHER | 1 | Jan 29, 2019 | clinicaltrials |
| NCT00611858 | Cetuximab, 5-FU and Radiation as Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer | terminated | Phase 2 | 13 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 8, 2019 | clinicaltrials |
| NCT01925274 | A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | terminated | Phase 2 | 19 | PfizerINDUSTRY | 4 | Jan 8, 2019 | clinicaltrials |
| NCT01523639 | A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis(G-LUCAS) | terminated | Phase 2 | 8 | Austrian Breast & Colorectal Cancer Study GroupNETWORK | 1 | Dec 19, 2018 | clinicaltrials |
| NCT02669914 | MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors | terminated | Phase 2 | 4 | Washington University School of MedicineOTHER | 1 | Nov 6, 2018 | clinicaltrials |
| NCT02216149 | Effects of S-1 and Capecitabine on Coronary Artery Blood Flow(FluoHeart) | terminated | Phase 2 | 20 | Heikki JoensuuOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT01613469 | Maintenance Chemotherapy After Neoadjuvant Chemoradiation Therapy for Distal Rectal Cancer | terminated | Phase 2 | 5 | Marks, John, M.D.INDIV | 1 | Aug 16, 2018 | clinicaltrials |
| NCT02508077 | FOLFIRI and Panitumumab in Treating Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer | terminated | Phase 2 | 1 | City of Hope Medical CenterOTHER | 1 | Aug 16, 2018 | clinicaltrials |
| NCT02654639 | Ph 2 Study of TAS-102 / Bevacizumab Maintenance Therapy Post Induction Chemotherapy in Metastatic Colorectal Cancer(ALEXANDRIA) | terminated | Phase 2 | 4 | Georgetown UniversityOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT00845039 | A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab(FC-4) | terminated | Phase 2 | 4 | Eli Lilly and CompanyINDUSTRY | 1 | Jul 2, 2018 | clinicaltrials |
| NCT02423954 | Study of Nivolumab Plus Chemotherapy in Patients With Advanced Cancer (NivoPlus)(NivoPlus) | terminated | Phase 1 / Phase 2 | 33 | Western Regional Medical CenterOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT01926769 | A Phase II Study to Determine the Safety and Efficacy of Second-line Treatment With Metformin and Chemotherapy (FOLFOX6 or FOFIRI) in the Second Line Threatment of Advanced Colorectal Cancer | terminated | Phase 2 | 2 | Gachon University Gil Medical CenterOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT00832299 | Neo-Adjuvant FOLFOX for Rectal Carcinoma | terminated | Phase 2 | 2 | Beth Israel Medical CenterOTHER | 1 | Mar 1, 2018 | clinicaltrials |
| NCT02119676 | Study of Ruxolitinib in Colorectal Cancer Patients | terminated | Phase 2 | 396 | Incyte CorporationINDUSTRY | 8 | Feb 13, 2018 | clinicaltrials |
| NCT02163187 | Sacral Neuromodulation (SNM) With InterStimTM for Bowel Dysfunction Following Surgery for Rectal Cancers With Sphincter Preservation | terminated | Phase 2 / Phase 3 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01729923 | A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer(ADAPT) | terminated | Phase 2 | 27 | University of WashingtonOTHER | 1 | Jan 16, 2018 | clinicaltrials |
| NCT00226941 | A Phase 1-2 Trial of Cetuximab in Combination With Oxaliplatin, Capecitabine, and Radiation Therapy Followed by Surgery for Locally-advanced Rectal Cancer | terminated | Phase 1 / Phase 2 | 23 | George Albert FisherOTHER | 1 | Dec 8, 2017 | clinicaltrials |
| NCT02473094 | Neoadjuvant Metformin in Association to Chemoradiotherapy for Locally Advanced Rectal Cancer(NEOMETRE) | terminated | Phase 2 | 3 | University of Campinas, BrazilOTHER | 1 | Nov 28, 2017 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT00625183 | Capecitabine, Oxaliplatin, Selenomethionine, and Radiation Therapy in Treating Patients Undergoing Surgery For Newly Diagnosed Stage II or III Rectal Adenocarcinoma | terminated | Phase 2 | 5 | Roswell Park Cancer InstituteOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | terminated | Phase 2 | 39 | Mayo ClinicOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT00003522 | Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine | terminated | Phase 2 | 1 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT00003485 | Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer | terminated | Phase 2 | 15 | Burzynski Research InstituteOTHER | 1 | Sep 28, 2017 | clinicaltrials |
| NCT01765582 | Sequential and Concurrent FOLFOXIRI/Bevacizumab Regimens Versus FOLFOX/Bevacizumab in First-Line Metastatic Colorectal Cancer(STEAM) | terminated | Phase 2 | 280 | Hoffmann-La RocheINDUSTRY | 1 | Sep 18, 2017 | clinicaltrials |
| NCT02175654 | Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab(PREVIUM) | terminated | Phase 2 | 15 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00423150 | Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) | terminated | Phase 2 | 86 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jun 8, 2017 | clinicaltrials |
| NCT00449163 | Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colorectal Cancer | terminated | Phase 2 | 25 | University of MiamiOTHER | 1 | May 11, 2017 | clinicaltrials |
| NCT02277093 | Pacritinib to Inhibit JAK/STAT Signaling in Refractory Colorectal Cancer | terminated | Phase 2 | 11 | Washington University School of MedicineOTHER | 1 | May 1, 2017 | clinicaltrials |
| NCT00126451 | A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer (0683-011)(TERMINATED) | terminated | Phase 2 | 16 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 10, 2017 | clinicaltrials |
| NCT00588900 | Irinotecan and Cediranib in Treating Patients With Metastatic Colorectal Cancer That Did Not Respond to Previous Oxaliplatin, Fluoropyrimidine, and Bevacizumab | terminated | Phase 2 | 5 | Alliance for Clinical Trials in OncologyOTHER | 1 | Apr 5, 2017 | clinicaltrials |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2017 | clinicaltrials |
| NCT00127036 | Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A) | terminated | Phase 2 | 65 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Mar 23, 2017 | clinicaltrials |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00276861 | Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer | terminated | Phase 2 | 10 | University of MiamiOTHER | 1 | Feb 8, 2017 | clinicaltrials |
| NCT01718808 | Cetuximab for Elderly Patients With mCRC | terminated | Phase 2 | 24 | Swiss Cancer InstituteOTHER | 1 | Jan 24, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 13, 2019source: clinicaltrials